Viking Therapeutics (VK2735) Investment Analysis

What this research found

Ahead of the Phase 3 VANQUISH readout for VK2735, Viking Therapeutics' dual GLP-1/GIP receptor agonist for obesity, K-Dense built a catalyst analysis that sizes the market, models bull, base and bear outcomes, and reverse-engineers what the company's roughly $6B market capitalization already implies. The probability-weighted expected value came out at $12.5B, a 109% expected return with a 3.3-to-1 risk/reward ratio, while the same model showed the market pricing in only a 26% chance of success under base-case peak sales of $12.1B.

• The roughly $6B market capitalization implies just a 26% probability of Phase 3 success if VK2735 reaches base-case peak sales of $12.1B. Inverting the calculation, a standard Phase 3 success rate of 65% would imply peak sales of only $4.7B, a 3.9% share of the US GLP-1 market.
• Probability-weighted expected value is $12.5B against the roughly $6B market cap, a 109% expected return. The bull case (20% probability, over 17% weight loss with under 5% discontinuation) values the company at $28.5B or $248 per share; the bear case (30% probability) at $1.6B or $14 per share.
• Phase 2 subcutaneous VK2735 produced 14.7% weight loss at 13 weeks with 13% discontinuation against 14% on placebo. The bar set by approved rivals is higher: 22.5% at 72 weeks for Zepbound and 14.9% at 68 weeks for Wegovy.
• The oral formulation is the weak link. In the August 2025 VENTURE-Oral trial 28% of patients discontinued against 18% on placebo, rising to 38% at the 120 mg dose, with nausea at 58%. The stock fell 37% on that release.
• A 2028 launch would open a four-year premium pricing window before US semaglutide generics are expected in January 2032, and roughly 11 years before tirzepatide generics in July 2039.
• Against the closest deal comparable, Roche's $3.1B acquisition of Carmot Therapeutics in December 2023, Viking trades at a 94% premium, partly explained by having Phase 2 complete rather than Phase 2-ready.

How it was done

Phase 2 results for VK2735 and competitor readouts were assembled from ClinicalTrials.gov registrations, company investor releases and FDA prescribing information, then benchmarked side by side on weight loss and discontinuation. A discounted cash flow model — 11% discount rate, 21% tax, 15% cost of goods, 30% SG&A, 2028 launch, 2040 patent expiry — produced risk-adjusted net present values across conservative, base and optimistic market-share scenarios, and was then inverted to back out the probability of success implied by the share price. Parallel strands set adverse-event thresholds against the Zepbound and Wegovy safety baselines, mapped GLP-1 patent expiries, and translated each scenario into defined-risk options structures such as bull call spreads, protective puts and risk reversals. The output was a 27-page illustrated report.

Data sources

• ClinicalTrials.gov — VANQUISH Phase 3 registrations NCT07104500 and NCT07104383, and VENTURE NCT06068946
• FDA prescribing information for Zepbound (tirzepatide) and Wegovy (semaglutide)
• Viking Therapeutics investor releases — VENTURE top-line results (February 2024) and VENTURE-Oral (August 2025)
• FDA Adverse Event Reporting System (FAERS), Q3 2024
• Evaluate GLP-1 market report — global market $53.5B in 2024, projected $156.7B by 2030
• Patent landscape data from DrugPatentWatch, IQVIA and Markman Advisors
• Roche–Carmot Therapeutics transaction terms, December 2023

Figures from this analysis

Outputs produced

• comparative_clinical_data.csv

  Structured CSV with clinical trial data for VK2735 and 3 competitors

• clinical_data_summary.md

  Comprehensive summary of trial designs and competitive benchmarks

• safety_baseline.csv

  Comparative adverse event rates for Zepbound, Wegovy, VK2735 and competitors

• safety_analysis_summary.md

  Safety signal profiling with safe harbor vs red flag thresholds

• valuation_model.py

  rNPV valuation model with market sizing, scenario analysis, and reverse engineering

• valuation_scenarios.csv

  rNPV outputs for various PoS and Peak Sales combinations

• valuation_analysis.md

  Valuation analysis interpreting implied market expectations

• 04_patent_cliff_analysis.py

  Patent cliff timing analysis script for competitor LOE dates